Solutions for COVID-19 research
COVID-19 continues to infect people worldwide. While vaccination campaigns have reduced the severity of many cases, new infections still occur, especially with the emergence of new variants. A significant number of individuals experience prolonged symptoms and complications, known as long COVID, which can affect their quality of life and ability to work. Whilst persistent outbreaks can strain healthcare systems, leading to resource shortages and impacting the care of non-COVID patients.
SARS-CoV-2, like all viruses, mutates over time. Some variants may spread more easily, evade immunity, or cause more severe disease. Monitoring and responding to these variants is crucial for public health.
Abcam offers a variety of tools used to help understand and accelerate infectious disease research, including SARS-CoV-2, the coronavirus that causes COVID-19. To help researchers navigate quickly to relevant products, listed below are antibodies, proteins, ELISAs and cell lines specific for the detection and analysis of human coronaviruses.
Antibodies for SARS CoV2
Abcam offers a variety of tools used to help understand and accelerate infectious disease research, including SARS-CoV-2. Our broad portfolio of products includes highly cited monoclonal and polyclonal antibodies, as well as an unrivaled range of recombinant monoclonal antibodies for your COVID-19 research needs. Our recombinant monoclonal antibodies have been extensively validated using knockout cell lines, providing specificity and, thus, reliability in your results.
Product highlights
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116]
- Validated in dot blot, ELISA, western blot, ICC/IF, and flow cytometry
Anti-SARS-CoV-2 Spike Glycoprotein S2 antibody [EPR25038-122]
- Highly cited
- Validated in dot blot, ELISA, western blot, ICC/IF, and flow cytometry
Rabbit monoclonal [EPR24334-118] to SARS-CoV-2 nucleocapsid protein
- Highly cited
- Validated in dot blot, ELISA, western blot, ICC/IF, IP, flow cytometry (intra), and IHC-P
ELISA Kits for SARS CoV2
Abcam's Universal Lateral Flow Assay Kit enables the simple and rapid development of proof-of-concept sandwich lateral flow immunoassays. It does so by removing the need to spray down capture antibodies on the test strips and to make gold conjugates with passive absorption, which typically requires expertise, specialized equipment, hands-on time, large amounts of antibodies, and rounds of optimization. Instead, any antibody pairs used can simply and rapidly be conjugated to the gold nanoparticles with our Lightning-Link and Gold conjugation technologies and combined with the universal strips, other reagents and buffers. The Universal Lateral Flow Assay Kit can also be used for antibody pair screening for assay development.
We also offer a full range of serological ELISA kits for the detection of antibodies and cytokines to SARS-CoV-2.
Product highlights
Universal Lateral Flow Assay Kit
- Universal
- Easy to use kit
SARS-CoV-2 IgM ELISA Kit
- Semi-quantitative
- Validated across a variety of sample types
SARS-CoV-2 IgG ELISA Kit
- Semi-quantitative
- Validated across a variety of sample types
Proteins and peptides for SARS CoV2
For COVID-19 research, Abcam provides a wide range of bioactive recombinant proteins, including variant Spike proteins from Brazil, South Africa, and the United Kingdom. We work to give researchers the tools they need to fight the coronavirus as the COVID-19 pandemic develops and new mutant variants are discovered. From SARS-CoV-2 to SARS and MERS coronaviruses, among others, we now offer distinct spike proteins, including the receptor binding domain (RBD), S1, S2, and full ectodomain spike proteins. There are His-, Fc-, and Avi-tag options available, and the bioactivity and lot-to-lot consistency of each protein we produce for coronavirus research are rigorously tested in-house.
Product highlights
Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Trimeric Spike Glycoprotein
- Recombinant full-length protein
Recombinant human coronavirus SARS-CoV-2 3CL protease protein (Active)
- Recombinant full-length protein
- Bioactive
Recombinant human coronavirus SARS-CoV-2 RNA-dependent RNA polymerase (RDRP) protein (Active)
- Recombinant full-length protein
- Bioactive
Cell lines for SARS CoV2
KO cell lines are used to investigate the impact of specific gene deletions on various cell functions. This approach facilitates the identification of potential therapeutic targets and expedites the development of novel treatments. Furthermore, KO cell lines serve as a valuable tool for evaluating the efficacy and safety of gene-editing techniques.
Our gene-edited cell lines, generated using CRISPR-Cas9 technology, precisely disrupt a specific gene within the cellular genome. These cell lines undergo extensive validation to ensure specificity, thereby enabling more rapid advancements in target validation, pathway elucidation, disease research, and related fields.
Our extensive catalog of COVID-19-related pre-established knockout cell lines and lysates enables researchers to obtain their desired knockout within five days. These resources are readily accessible, increasingly pertinent, and meticulously prepared, offering an efficient solution for research needs. The knockout cell lines are suitable for antibody validation and functional assays. With a comprehensive portfolio available, researchers can significantly accelerate their COVID-19 investigations.